Novavax shares are trading lower after the FDA left the company out when providing updates on its emergency use authorization (EUA) approval for vaccines.
Portfolio Pulse from Benzinga Newsdesk
Novavax shares declined after the FDA excluded the company from its latest updates on emergency use authorization for vaccines.
August 22, 2024 | 7:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novavax shares fell due to the FDA not including the company in its recent emergency use authorization updates for vaccines.
The exclusion of Novavax from the FDA's EUA updates likely signals a delay or issue with their vaccine approval process, leading to a negative market reaction and a drop in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100